Contralateral prophylactic mastectomy: Efficacy and determinants of significant histologic findings

Goldflam, Katja; Gershenwald, Jeffrey E.; Hunt, Kelly K.; Singletary, S. Eva; Mirza, Nadeem Q.; Arun, B; Babiera, Gildy; Kuerer, Henry Mark; Ross, Merrick I.; Meric‐Bernstam, Funda

doi:10.1007/bf02524104

Cited by 27 publications

(55 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Four women opted for prophylactic bilateral mastectomy in order to avoid close post-operative follow-up. All decisions were approved by a multidisciplinary board of surgeons, oncologists, radiologists, psychologists and radiation oncologists (18,19). All patients had breast reconstruction, immediately in 14 cases and one year later in one case.…”

Section: Study Cohortmentioning

confidence: 99%

Invasive lobular carcinoma of the breast: MRI pathological correlation following bilateral total mastectomy

et al. 2012

View full text Add to dashboard Cite

Section: Study Cohortmentioning

confidence: 99%

Invasive lobular carcinoma of the breast: MRI pathological correlation following bilateral total mastectomy

et al. 2012

View full text Add to dashboard Cite

“…These findings are also consistent with our recent publication regarding the M. D. Anderson Cancer Center experience with contralateral prophylactic mastectomy in 239 patients with unilateral breast carcinoma. 13 In the contralateral prophylactic mastectomy study we found that patients who had concurrent DCIS and ipsilateral high-risk lesions (ADH and or LN) were more likely to have significant occult additional high-risk lesions and or carcinoma within the contralateral prophylactic mastectomy specimen compared with patients without concurrent ipsilateral high-risk lesions. 13 Breast-conserving surgery followed by wholebreast radiation therapy did not become the preferred treatment for DCIS at M. D. Anderson until the mid1990s, after publication of long-term results of randomized data by the NSABP.…”

Section: Discussionmentioning

confidence: 74%

“…13 In the contralateral prophylactic mastectomy study we found that patients who had concurrent DCIS and ipsilateral high-risk lesions (ADH and or LN) were more likely to have significant occult additional high-risk lesions and or carcinoma within the contralateral prophylactic mastectomy specimen compared with patients without concurrent ipsilateral high-risk lesions. 13 Breast-conserving surgery followed by wholebreast radiation therapy did not become the preferred treatment for DCIS at M. D. Anderson until the mid1990s, after publication of long-term results of randomized data by the NSABP. 14,16 Our present findings regarding the impact of radiation therapy on IBCR in patients with DCIS were consistent with those from previous studies.…”

Section: Discussionmentioning

confidence: 74%

Impact of concurrent proliferative high‐risk lesions on the risk of ipsilateral breast carcinoma recurrence and contralateral breast carcinoma development in patients with ductal carcinoma in situ treated with breast‐conserving therapy

Adepoju

Symmans

Babiera

et al. 2005

Cancer

View full text Add to dashboard Cite

BACKGROUNDThe purpose of the study was to determine the risk of ipsilateral breast carcinoma recurrence (IBCR) and contralateral breast carcinoma (CBC) development in patients with a concurrent diagnosis of ductal carcinoma in situ (DCIS) with atypical ductal hyperplasia (ADH), atypical lobular hyperplasia (ALH), or lobular carcinoma in situ (LCIS).METHODSRecords of all 307 patients with DCIS treated with breast‐conserving treatment (BCT) from 1968 to 1998 were analyzed. Initial pathology reports and all slides available were re‐reviewed for evidence of ADH, ALH, or LCIS. Actuarial local recurrence rates were calculated.RESULTSFifty‐five cases of DCIS were associated with ADH, 11 with ALH or LCIS, and 14 with both ADH and ALH or LCIS. Overall, IBCR occurred in 14% and no significant difference in the IBCR rate was identified for patients with proliferative lesions compared with patients without these lesions (P = 0.38). Development of CBC in patients with concurrent DCIS and ADH was 4.4 times (95% confidence interval [CI], 1.44–13.63) that in patients with DCIS alone (P < 0.01). The 15‐year cumulative rate of CBC development was 22.7% in patients with ALH or LCIS compared with 6.5% in patients without these lesions (P = 0.30) and 19% in patients with ADH compared with 4.1% in patients with DCIS alone (P < 0.01).CONCLUSIONThe risk of CBC development is higher with concurrent ADH than in patients with DCIS alone, and these patients may therefore be appropriate candidates for additional chemoprevention strategies. Concurrent ADH, ALH, or LCIS with DCIS is not a contraindication to BCT. Cancer 2006. © 2005 American Cancer Society.

show abstract

“…Existing data suggest that contralateral risk-reducing mastectomy may diminish by as much as 95% the risk of developing breast cancer in moderate-and high-risk women, particularly in women with ipsilateral breast cancer or known BRCA1/BRCA2 mutation [2,5,6]. Using the Anderson model to predict the risk of developing contralateral breast cancer, McDonnell et al [7] estimated that contralateral risk-reducing mastectomy resulted in a risk reduction of 64%.…”

Section: Benefits Of Contralateral Risk-reducing Mastectomymentioning

confidence: 99%

Contralateral risk-reducing mastectomy in young women

Merck

2010

Breast Cancer Res Treat

View full text Add to dashboard Cite

show abstract

Contralateral prophylactic mastectomy: Efficacy and determinants of significant histologic findings

Cited by 27 publications

References 0 publications

Invasive lobular carcinoma of the breast: MRI pathological correlation following bilateral total mastectomy

Invasive lobular carcinoma of the breast: MRI pathological correlation following bilateral total mastectomy

Impact of concurrent proliferative high‐risk lesions on the risk of ipsilateral breast carcinoma recurrence and contralateral breast carcinoma development in patients with ductal carcinoma in situ treated with breast‐conserving therapy

Contralateral risk-reducing mastectomy in young women

Contact Info

Product

Resources

About